China regulator tightens guideline on biological products, including vaccines
[BEIJING] China's market regulator said on Monday it had tightened up a guideline for inspection of biological products, including vaccines, before a batch is sold or imported.
The new guideline, effective from March 1 next year, adds a requirement that provincial-level medical product regulators are responsible for investigating major flaws that could impact product quality in companies' manufacturing process in their region, State Administration For Market Regulation said on its website.
The new guideline also specifies situations where inspection of pre-sale or pre-imported batches of such products could be waived, SAMR said.
China has allowed vaccines, if they are used to cope with infectious disease epidemics or other emergencies, to be exempted from inspection procedures, known as lot release, after approval from State Council's medical product regulating department.
REUTERS
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
Putin plans to meet Xi in China days after his new term starts
Biden vetoes bid to repeal US labour board rule on contract, franchise workers
Economic leaders of South Korea, Japan, China say FX volatility is a risk
US automakers win extension on use of Chinese graphite in EV tax credits
US service sector contracts in April; price pressures up
Thaksin’s daughter calls central bank independence an ‘obstacle’